Navigation Links
High-risk women reluctant to take tamoxifen to prevent breast cancer, U-M study finds
Date:12/2/2009

ANN ARBOR, Mich. Even when women at high-risk of breast cancer are well-informed about the risks and benefits of using the drug tamoxifen for prevention, only 6 percent said they were likely to take it.

Researchers at the University of Michigan Comprehensive Cancer Center created a decision aid designed to inform women about the risks and benefits associated with tamoxifen, a drug that was first used to stop breast cancer from returning and has recently been shown to prevent breast cancer in the first place.

The U-M decision aid gave objective information about tamoxifen and was tailored to each woman's health history. The study targeted women who were at high risk of developing breast cancer within the next five years; 632 women participated.

"Tailored information is critical because the risks and benefits vary across women. This is one of the most detailed tailored decision aids to address breast cancer prevention. The information about the risks and benefits of tamoxifen was tailored to each woman's health history. That means, when women read this decision aid, they learned about how the drug was likely to affect them given their age, race, breast cancer history and medical history," says lead author Angela Fagerlin, Ph.D., associate professor of internal medicine at the U-M Medical School and a research investigator at the VA Ann Arbor Healthcare System.

After viewing the decision aid, 41 percent of women could correctly answer six questions about the risks and benefits of tamoxifen, while 63 percent correctly answered at least five of the six questions.

Despite this understanding, only 29 percent of women said they were likely to seek out more information about tamoxifen, and only 29 percent said they would ask their doctor about it. A scant 6 percent of women said they were likely to take tamoxifen.

Three months later, the researchers found that fewer than 1 percent of participants had started taking tamoxifen, and fewer than 6 percent had either talked to their doctor or sought more information.

Results of the study appear online in the journal Breast Cancer Research and Treatment.

"For any given woman, there is not a right or wrong answer in regards to whether she should take tamoxifen to prevent a first diagnosis of breast cancer. The goal of decision aids is to explain the risks and benefits in a clear way so that the woman is able to weigh these factors and make an informed decision about what is best for her," Fagerlin says.

While as many as 10 million women could be eligible to take tamoxifen to prevent breast cancer, few choose to do so.

Side effects were the biggest concern about tamoxifen cited in this study, with 80 percent of the participants worried about this. The side effects of tamoxifen include hormonal symptoms, including hot flashes, and sexual problems, as well as rare incidences of endometrial cancer, blood clots or cataracts.

"Experts have bemoaned the dearth of women taking these pills, worried that word has not gotten out about tamoxifen's ability to prevent breast cancer in high risk women. Our study shows that even when the word does get out, most women are too concerned about the pill's side effects to want to take it," says senior author Peter Ubel, M.D., professor of internal medicine and director of the Center for Behavioral and Decision Sciences in Medicine at U-M.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Mammograms May Boost Cancer Risk in High-Risk Women
2. Mammography may increase breast cancer risk in some high-risk women
3. Mammography May Increase Breast Cancer Risk in Some High-Risk Women
4. Should noninvasive ventilation be considered a high-risk procedure during an epidemic?
5. MitraClip(R) Therapy Data Demonstrate Significant Reduction in Mitral Valve Annulus Dimensions in High-Risk Patients With Functional Mitral Regurgitation
6. Study finds promise in combined transplant/vaccine therapy for high-risk leukemia
7. NCCN Stresses Importance of PSA Testing in High-Risk Men
8. New drug for children with high-risk leukemia
9. Barriers to diabetes care include restaurants and high-risk lifestyles, says international review
10. Salt Boosts Blood Pressure in High-Risk Patients
11. Ovary Removal Lowers Odds of Cancer in High-Risk Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2016)... (PRWEB) , ... February 14, 2016 , ... ... themselves without trained eating disorders professionals near their residence. The nature of the ... no transportation, child care or time allotted at work to make traditional appointments. ...
(Date:2/13/2016)... ... ... Cypress in Sun City is the place to be on March 3rd to learn about ... will be hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting advancements will ... offers. In addition, prizes will be given away and light refreshments will be served. ...
(Date:2/13/2016)... , ... February 13, 2016 , ... Many individuals looking ... protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved into ... once more, but without the high-carb repercussions. IsoPasta has 30 grams of protein ...
(Date:2/13/2016)... ... February 13, 2016 , ... ... (INS) states that vein visualization technology should be used to ensure patient safety ... the world, the INS Standards mandate the use of vein visualization technology in ...
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or “honeymoon” stage ... to perfection, go out of their way to be romantic, and may exaggerate a ... look at any online dating profile. , A recent study from Queendom.com ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... --  HeartWare International, Inc . (NASDAQ: HTWR ) ... its financial results for the three and 12 months ... at 8:00 a.m. ET.  The company plans to release ... webcast.  On the conference call and webcast, management will ... quarter and business outlook.   --> ...
(Date:2/12/2016)... , Feb. 12, 2016  Sequent Medical, Inc. ... a study to evaluate the safety and effectiveness of ... treatment of ruptured intracranial aneurysms.  Prof Laurent Spelle ... in Paris, France and Principal ... France and Germany.  Although ...
(Date:2/12/2016)... 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ) ... will ring the Nasdaq Closing Bell at the Nasdaq ... at 4:00 p.m. ET on Tuesday, February 16, ... Adrian Adams , will perform the honorary bell ... p.m. ET.  A live webcast will be available at: ...
Breaking Medicine Technology: